The Bundibugyo Ebola outbreak escalated sharply in 48 hours: suspected cases more than doubled, from 246 on May 16 to more than 500 by May 19, and deaths rose from about 80 to more than 130, with confirmed cases now in Bunia, Kampala, Goma, and Kinshasa. On May 18, the Trump administration responded with a first: a US entry ban on non-citizens who have been in the DRC, Uganda, or South Sudan in the previous 21 days, plus airport screening, framed as a Title 42 public-health order in effect for 30 days. The same day, the first American was confirmed infected — Dr. Peter Stafford, a missionary physician who had worked in Bunia since 2023. The CDC says the risk to the US public is "low."

1. Close the Door (CDC / DHS)

With confirmed cases in four cities and an infected American, a 21-day entry restriction buys containment time.

You act early precisely because the risk is still low. The CDC and DHS imposed the restriction under Title 42, the same public-health authority used during COVID, on non-US passport holders who have recently been in the three affected countries. The administration's logic is layered defense: the outbreak has reached two national capitals and is showing transmission ro health care workers, an American is already infected, and suspected cases more than doubled in two days. A temporary entry restriction plus airport screening costs little and buys time to map the outbreak and ready hospitals.

The "low risk" line is the point, not the contradiction. The CDC's own assessment that the public risk is low is the case for acting now rather than later — the cheapest moment to wall off a pathogen is before it has a foothold. The administration would rather over-prepare for a hemorrhagic fever with an estimated 25-40% fatality rate than be caught flat, especially after a spring in which it was accused of gutting the agencies that detect outbreaks early.

2. Bans Don't Work, They Backfire (Krutika Kuppalli, Katelyn Jetelina, Jeanne Marrazzo)

Ebola doesn't travel the way the ban assumes — and the ban makes containment harder.

A virus spread by bodily fluids is not stopped by a passport check. Krutika Kuppalli, an infectious-diseases specialist who previously worked for the WHO, says travel bans don't stop viral spread and can actively impede containment. Katelyn Jetelina's "Your Local Epidemiologist" newsletter made the blunter case: bans don't work unless you halt all travel from everywhere, and they are usually "a political move — a tool to show the public that the government is responding." Jeanne Marrazzo, who runs the Infectious Diseases Society of America, says policies that single out non-citizens won't keep a virus from crossing a border.

The CDC knows it. Celine Gounder's read is that the CDC's own Title 42 document concedes the problem: Ebola spreads through direct contact, not casual air travel, and arrival temperature screening misses anyone still in the incubation period. Worse, a geographic ban pushes travelers onto indirect routes that are harder to trace, and it deters the cross-border cooperation that actually ends outbreaks. Europe's response was the inverse: the ECDC is deploying medics into the region while the US restricts entry.

3. Who Cares About All This — The Only Important Thing Is the Drug Trial (Thomas Geisbert, Amanda Rojek, WHO)

The thing that saves lives is a clinical trial, not a customs line.

The real decision this week is medical, not immigration. WHO is readying a clinical trial of two experimental treatments — Gilead's remdesivir and MBP134, a Mapp Biopharmaceutical antibody cocktail that targets multiple Ebola species and rescued five of six infected monkeys in a 2019 study — pending ethics approval in DRC and Uganda. That trial, not the travel order, is what could actually lower the fatality rate in Ituri.

There's a real question here. There is no licensed Bundibugyo vaccine, so WHO's R&D Blueprint group is weighing whether to deploy Merck's Ervebo — licensed only for the Zaire strain — off-label. Thomas Geisbert, a virologist at the University of Texas Medical Branch, estimates it might be 50% effective against Bundibugyo based on primate data; researcher Amanda Rojek cautions that "it's very early days in this outbreak, and things change very, very quickly." Deploy a half-a-chance vaccine into a spreading outbreak, or wait for evidence that may come too late: that is the fork that matters, and it has nothing to do with who lands at JFK.

Where This Lands

The administration says a temporary entry ban is cheap insurance against a virus, with an estimated 25-40% fatality rate, that just reached two capitals. The epidemiologists say the ban has no basis in how Ebola actually spreads, misses incubating travelers, and deters the cooperation containment depends on. And the scientists say both sides are arguing about the wrong thing, because the lives are saved or lost in a clinical trial in Bunia, not at a US port of entry.

Sources